Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Response to: "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis".

Tive LA, Viktrup L, Shelton D.

J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):548. doi: 10.4103/joacp.JOACP_155_18. No abstract available.

2.

When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.

Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS.

Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

3.

Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.

Riddle MC, McDaniel PA, Tive LA.

Diabetes Care. 1997 Jun;20(6):992-4.

PMID:
9167112
5.

Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist.

Tive LA, Pick CG, Paul D, Roques BP, Gacel GA, Pasternak GW.

Eur J Pharmacol. 1992 Jun 5;216(2):249-55.

PMID:
1327812
6.

Pharmacological characterization of nalorphine, a kappa 3 analgesic.

Paul D, Pick CG, Tive LA, Pasternak GW.

J Pharmacol Exp Ther. 1991 Apr;257(1):1-7.

PMID:
1850462

Supplemental Content

Support Center